Table 2.
Prognostic analysis of the early‐stage cohort of patients with mucoepidermoid carcinoma (N = 69)
| Factor | N | Disease‐free survival | ||
|---|---|---|---|---|
| HR | 95% CI | P value | ||
| Age (y) | ||||
| <60 | 42 | 1.00 | ||
| ≥60 | 27 | 0.68 | 0.12‐3.76 | .654 |
| Sex | ||||
| Male | 32 | 1.00 | ||
| Female | 37 | 1.84 | 0.33‐10.09 | .468 |
| Primary site | ||||
| Major gland | 39 | 1.00 | ||
| Minor gland | 30 | 2.86 | 0.52‐15.79 | .209 |
| CRTC1/3‐MAML2 | ||||
| Positive | 52 | 1.00 | ||
| Negative | 17 | 3.88*10−9 | NA | .133 |
| Tumor grade | ||||
| Low | 59 | 1.00 | ||
| Intermediate/high | 10 | 1.38*10−9 | NA | .095 |
| Surgical margin | ||||
| Negative | 58 | 1.00 | ||
| Close/positive | 11 | 0.97 | 0.11‐8.46 | .981 |
| Neck dissection | ||||
| Yes | 3 | 1.00 | ||
| No | 66 | 2.11*108 | NA | .355 |
| Postoperative therapy | ||||
| Not performed | 67 | 1.00 | ||
| Performed | 2 | 4.02*10−9 | NA | .700 |
Follow‐up median, 45 mo (range, 2‐263).
Abbreviations: CI, confidence interval; HR, hazard ratio; NA, not available.